• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

POP7在透明细胞肾细胞癌中的预后价值及免疫作用

Prognostic Value and Immunological Role of POP7 in Clear Cell Renal Cell Carcinoma.

作者信息

Lou Ning, Meng Xiangui, Yu Tiexi, Li Weiquan, Lv Xin, Han Weiwei, Xiao Wen, Shi Ying

机构信息

Department of Urology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.

Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.

出版信息

Pharmgenomics Pers Med. 2024 Nov 26;17:521-534. doi: 10.2147/PGPM.S469247. eCollection 2024.

DOI:10.2147/PGPM.S469247
PMID:39620194
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11608043/
Abstract

BACKGROUND

Studies have found that RNA-binding proteins (RBPs) are participated in the occurrence or development of tumours. However, the role of processing of precursor family (POP family) in clear cell renal cell carcinoma (ccRCC) has not been studied yet. Here, we analyzed the expression and prognostic value of POP family in ccRCC analyzed and subsequently revealed the relationship between POP7 and immune infiltration in ccRCC patients.

METHODS

POP family expression in cancer and normal tissues was analyzed in Cancer Genome Atlas pan-cancer (TCGA-pan-cancer). Kaplan-Meier (KM) survival analysis, univariable and multivariable analysis demonstrated the survival of ccRCC with POP family in Kidney Clear Cell Carcinoma (TCGA-KIRC). POP7 mRNA and protein expression were verified by Gene Expression Omnibus (GEO) data, the quantitative real-time polymerase chain reaction (qRT-PCR), and Office of Cancer Clinical Proteomics Research (CPTAC). The diagnostic ability of POP7 mRNA and protein expression was achieved with ROC curves. Gene Set Enrichment Analysis (GSEA) and TiMER2 evaluated pathogenesis role and immune infiltration of POP7in ccRCC.

RESULTS

There is a significant difference in expression of POP family in TCGA-pan-cancer, especially in ccRCC. KM survival analysis, univariable and multivariable analysis demonstrated low expression of POP7 and was associated with poor OS and poor DFS. GEO data, the qRT-PCR, and CPTAC verified the high expression of POP7 mRNA and protein in ccRCC. ROC curves verified a valuable diagnostic ability of POP7 in mRNA and protein expression. GSEA demonstrated POP7 was associated with CD8+cells, CD4+cells, natural killer (NK) cells, and helper T (TH1) cells. TiMER2 results indicated POP7 had a positive correlation with T cell regulatory (Tregs) and myeloid-derived suppressor cells (MDSC) in ccRCC and was an immunosuppressor for ccRCC.

CONCLUSION

POP7 was a reliable immunosuppressor, predictor and biomarker for ccRCC.

摘要

背景

研究发现RNA结合蛋白(RBPs)参与肿瘤的发生或发展。然而,前体家族加工蛋白(POP家族)在肾透明细胞癌(ccRCC)中的作用尚未得到研究。在此,我们分析了POP家族在ccRCC中的表达及预后价值,并随后揭示了POP7与ccRCC患者免疫浸润之间的关系。

方法

在癌症基因组图谱泛癌(TCGA-泛癌)中分析了POP家族在癌组织和正常组织中的表达。Kaplan-Meier(KM)生存分析、单变量和多变量分析证明了POP家族在肾透明细胞癌(TCGA-KIRC)中对ccRCC生存的影响。通过基因表达综合数据库(GEO)数据、定量实时聚合酶链反应(qRT-PCR)和癌症临床蛋白质组学研究办公室(CPTAC)验证了POP7 mRNA和蛋白的表达。通过ROC曲线评估POP7 mRNA和蛋白表达的诊断能力。基因集富集分析(GSEA)和TiMER2评估了POP7在ccRCC中的发病机制作用和免疫浸润情况。

结果

POP家族在TCGA-泛癌中的表达存在显著差异,尤其是在ccRCC中。KM生存分析、单变量和多变量分析表明POP7低表达与较差的总生存期(OS)和无病生存期(DFS)相关。GEO数据、qRT-PCR和CPTAC验证了ccRCC中POP7 mRNA和蛋白的高表达。ROC曲线验证了POP7在mRNA和蛋白表达方面具有有价值的诊断能力。GSEA表明POP7与CD8+细胞、CD4+细胞、自然杀伤(NK)细胞和辅助性T(TH1)细胞相关。TiMER2结果表明,在ccRCC中POP7与调节性T细胞(Tregs)和髓源性抑制细胞(MDSC)呈正相关,是ccRCC的免疫抑制因子。

结论

POP7是ccRCC可靠的免疫抑制因子、预测指标和生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c566/11608043/08ee605e06a8/PGPM-17-521-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c566/11608043/da5f76df934c/PGPM-17-521-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c566/11608043/2c4a8d8a1a83/PGPM-17-521-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c566/11608043/d25e79f899ef/PGPM-17-521-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c566/11608043/1b0c2f895d9e/PGPM-17-521-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c566/11608043/876d2861e3bc/PGPM-17-521-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c566/11608043/0496bcf0f898/PGPM-17-521-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c566/11608043/08ee605e06a8/PGPM-17-521-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c566/11608043/da5f76df934c/PGPM-17-521-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c566/11608043/2c4a8d8a1a83/PGPM-17-521-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c566/11608043/d25e79f899ef/PGPM-17-521-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c566/11608043/1b0c2f895d9e/PGPM-17-521-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c566/11608043/876d2861e3bc/PGPM-17-521-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c566/11608043/0496bcf0f898/PGPM-17-521-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c566/11608043/08ee605e06a8/PGPM-17-521-g0007.jpg

相似文献

1
Prognostic Value and Immunological Role of POP7 in Clear Cell Renal Cell Carcinoma.POP7在透明细胞肾细胞癌中的预后价值及免疫作用
Pharmgenomics Pers Med. 2024 Nov 26;17:521-534. doi: 10.2147/PGPM.S469247. eCollection 2024.
2
High Expression of DNTTIP1 Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma.DNTTIP1高表达预示着透明细胞肾细胞癌的不良预后。
Pharmgenomics Pers Med. 2023 Jan 6;16:1-14. doi: 10.2147/PGPM.S382843. eCollection 2023.
3
is related to the poor prognosis and immune infiltration in clear cell renal cell carcinoma.与透明细胞肾细胞癌的不良预后和免疫浸润相关。
Transl Cancer Res. 2025 Feb 28;14(2):827-842. doi: 10.21037/tcr-24-449. Epub 2025 Feb 26.
4
The Downregulation of Prognosis- and Immune Infiltration-Related Gene CYFIP2 Serves as a Novel Target in ccRCC.预后与免疫浸润相关基因CYFIP2的下调作为ccRCC的新靶点
Int J Gen Med. 2021 Oct 11;14:6587-6599. doi: 10.2147/IJGM.S335713. eCollection 2021.
5
Upregulated GSDMB in Clear Cell Renal Cell Carcinoma Is Associated with Immune Infiltrates and Poor Prognosis.上调的 GSDMB 在透明细胞肾细胞癌中与免疫浸润和不良预后相关。
J Immunol Res. 2021 Dec 16;2021:7753553. doi: 10.1155/2021/7753553. eCollection 2021.
6
A comprehensive analysis of the prognostic value and immune infiltration of low expression DBT in clear cell renal cell carcinoma.透明细胞肾细胞癌中低表达DBT的预后价值及免疫浸润的综合分析
Front Pharmacol. 2022 Oct 10;13:1002588. doi: 10.3389/fphar.2022.1002588. eCollection 2022.
7
ERBB2 is a potential diagnostic and prognostic biomarker in renal clear cell carcinoma.ERBB2 是肾透明细胞癌潜在的诊断和预后生物标志物。
Sci Rep. 2024 Oct 1;14(1):22775. doi: 10.1038/s41598-024-73574-7.
8
A Novel Cuprotosis-Related Gene FDX1 Signature for Overall Survival Prediction in Clear Cell Renal Cell Carcinoma Patients.一种新型的铜死亡相关基因 FDX1 标志物,用于预测透明细胞肾细胞癌患者的总生存期。
Biomed Res Int. 2022 Sep 5;2022:9196540. doi: 10.1155/2022/9196540. eCollection 2022.
9
[Expression and significance of fibroblast growth factor receptor 2 in clear cell renal cell carcinoma].成纤维细胞生长因子受体2在肾透明细胞癌中的表达及意义
Beijing Da Xue Xue Bao Yi Xue Ban. 2022 Aug 18;54(4):628-635. doi: 10.19723/j.issn.1671-167X.2022.04.008.
10
LPCAT3 regulates the immune infiltration and prognosis of ccRCC patients by mediating ferroptosis and endoplasmic reticulum stress.LPCAT3通过介导铁死亡和内质网应激来调节ccRCC患者的免疫浸润和预后。
Discov Oncol. 2025 Apr 19;16(1):574. doi: 10.1007/s12672-025-02283-y.

本文引用的文献

1
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
2
Predicting Recurrence After Radical Surgery for High-Risk Renal Cell Carcinoma: Development and Internal Validation of the "TOWARDS" Score.高危肾细胞癌根治性手术后复发的预测:“迈向”评分的建立与内部验证。
Ann Surg Oncol. 2024 May;31(5):3513-3522. doi: 10.1245/s10434-024-14963-0. Epub 2024 Jan 29.
3
Hsa_circ_0086414/transducer of ERBB2 (TOB2) axis-driven lipid elimination and tumor suppression in clear cell renal cell cancer via perilipin 3.
Hsa_circ_0086414/ERBB2转导蛋白(TOB2)轴通过脂滴包被蛋白3驱动透明细胞肾细胞癌中的脂质清除和肿瘤抑制。
Int J Biol Macromol. 2024 Mar;261(Pt 1):129636. doi: 10.1016/j.ijbiomac.2024.129636. Epub 2024 Jan 23.
4
Established and emerging biomarkers of immunotherapy in renal cell carcinoma.肾细胞癌免疫治疗的既定和新兴生物标志物。
Immunotherapy. 2024 Apr;16(6):405-426. doi: 10.2217/imt-2023-0267. Epub 2024 Jan 24.
5
Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma.肾细胞癌中酪氨酸激酶抑制剂耐药的机制
Cancer Drug Resist. 2023 Dec 28;6(4):858-873. doi: 10.20517/cdr.2023.89. eCollection 2023.
6
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
7
T proliferating cells derived autophagy signature associated with prognosis and immunotherapy resistance in a pan-cancer analysis.在一项泛癌分析中,T增殖细胞衍生的自噬特征与预后和免疫治疗耐药性相关。
iScience. 2023 Dec 8;27(1):108701. doi: 10.1016/j.isci.2023.108701. eCollection 2024 Jan 19.
8
Advances in research on molecular markers in immune checkpoint inhibitor-associated myocarditis.免疫检查点抑制剂相关心肌炎分子标志物的研究进展
Cancer Innov. 2023 Nov 28;2(6):439-447. doi: 10.1002/cai2.100. eCollection 2023 Dec.
9
Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma: A Review.肾切除术治疗局部晚期和转移性肾细胞癌前的免疫检查点抑制剂治疗:综述
JAMA Oncol. 2024 Feb 1;10(2):240-248. doi: 10.1001/jamaoncol.2023.5269.
10
Bioinformatics analysis of human kallikrein 5 () expression in metaplastic triple-negative breast cancer.人组织激肽释放酶5()在化生性三阴性乳腺癌中表达的生物信息学分析
Cancer Innov. 2023 Oct 15;2(5):376-390. doi: 10.1002/cai2.96. eCollection 2023 Oct.